<DOC>
	<DOC>NCT00146770</DOC>
	<brief_summary>This study is being conducted to collect additional long-term efficacy and safety data of Aldurazyme® (laronidase) patients with MPS I disease. Patients who were previously enrolled in the Phase 3 Double-Blind Study will be enrolled in this study.</brief_summary>
	<brief_title>Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis I</mesh_term>
	<criteria>The patient or patient's legal guardian must provide written informed consent prior to any protocolrelated procedures being performed. The patient must have successfully completed Study ALID00399 (who received 21 of 26 consecutive weekly infusions). The patient has not experienced any safety issues that would contraindicate participation in the Extension study. A female patient of childbearing potential must have a negative pregnancy test at entry The patient is pregnant or lactating. The patient has received an investigational drug within 30 days prior to the study enrollment. The patient has a medical condition, serious intercurrent illness, or other extenuating circumstance that may significantly interfere with study compliance including all prescribed evaluations and followup activities</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>